The role of observational studies in the evaluation of treatments is a long-standing and contentious topic. 1 In this issue of the Journal, Concato et al. 2 and Benson and Hartz 3 report that observational studies give results similar to those of randomized, controlled trials. If these claims lead to more observational studies of therapeutic interventions and fewer randomized, controlled trials, we see considerable dangers to clinical research and even to the well-being of patients.
casts doubt on the validity of the conclusion that observational studies produce the same answers, in general, as randomized, controlled trials.
Screening for breast cancer is one of the five issues examined by Concato et al. 2 They do not cite individual studies but, instead, refer to a meta-analysis that found that mammography had a strong protective effect against death from breast cancer in both observational studies and randomized, controlled trials of breast-cancer screening. This meta-analysis made no allowance for the quality of the studies it incorporated. Such an approach contrasts sharply with a more recent meta-analysis 4 of the relevant high-quality randomized, controlled trials on the topic. The authors of that meta-analysis concluded that there was little evidence of benefit of screening for breast cancer. Hence, the estimates of the magnitude of the effect of screening in case-control studies and good randomized, controlled trials are, in fact, very different.
Other medical topics covered in the study by Concato et al. 2 include the influence of treatment for high blood pressure on the risk of stroke and coronary heart disease. The observational studies they reported were general population studies that included no data on antihypertensive treatment. Thus, the only evidence that antihypertensive drugs reduce the risk of stroke and heart disease comes from randomized, controlled trials.
The study by Benson and Hartz 3 summarizes the evidence from observational studies and randomized, controlled trials for 18 separate therapeutic comparisons (7 cardiologic and 11 noncardiologic) in just four paragraphs of text and two figures. Three further topics have then been selected for more detailed presentation (a selection bias?). Such lack of detail regarding most of the topics means that readers have no information on which to agree with or reject the authors' findings.
The issue of the comparative merits of coronary-artery bypass grafting and percutaneous transluminal coronary angioplasty is a case in point. The classification of patients into high-risk and low-risk groups is not explained. The observational studies appear to show that coronary-artery bypass grafting is inferior in low-risk patients, although the randomized, controlled trials do not. Furthermore, the data on diabetic patients are from a post hoc subgroup analysis in the Bypass Angioplasty Revascularization Investigation (BARI). Subgroup analyses often exaggerate differences between treatments in randomized, controlled trials, 5 so this comparison of the types of studies may suffer from a double dose of selection bias, with sources of bias in each type of study design.
The first example discussed by Benson and Hartz, the use of nifedipine in patients with coronary artery disease, reminds one of the fact that observational research on calcium-channel antagonists has provoked concern about the safety of these drugs. All such claims from observational studies have been hotly disputed, and the available evidence from randomized, controlled trials is as yet insufficient for definitive conclusions to be drawn. Thus, there is all the more reason to require additional evidence from major randomized, controlled trials, such as the ACTION trial, 6 which compares nifedipine and placebo in coronary heart disease.
Several of Benson and Hartz's examples, such as the Coronary Artery Surgery Study and BARI, nicely
illustrate the merits of enhancing a randomized, controlled trial by the addition of observational data from a concurrent registry of all nonrandomized patients in the same centers. This approach improves the quality of observational research, since the same rigorous attention to detail in defining eligible patients, maintaining follow-up, and recording outcomes is applied in both the randomized and the observational cohorts. The observational cohort may still suffer from selection bias, but there is a greater likelihood that its causes can be identified.
It is likely that the studies used in both reports 2, 3 are a highly selected sample, since it is rarely sensible for a therapeutic question to be equally and simultaneously addressed by both experimentation and observation. This factor may explain why the authors refer to the overall paucity of therapeutic questions evaluated in both randomized, controlled trials and observational studies. Regulatory authorities appropriately require randomized, controlled trials as the prime acceptable evidence for drug licensing, and medical journals have become reluctant to publish claims for treatments based on observational data. Recent examples demonstrate that such concern is not merely theoretical. The Heart and Estrogen/Progestin Replacement Study, 7 the Heart Outcomes Prevention Evaluation Study, 8 and the Beta-Carotene and Retinal Efficacy Trial 9 helped to restrain earlier observational claims that hormonereplacement therapy reduces the risk of coronary heart disease, vitamin E lowers the risk of cardiovascular disease, and beta carotene lowers the risk of lung cancer.
In some areas, such as monitoring for drug toxicity or studying risk factors for disease, we must rely on observational data. Detection of serious but rare side effects requires very large numbers of patients and can be achieved only through analysis of records from routine clinical practice. For some treatments, ethical considerations, practicality, clinical judgment, or unwillingness on the part of patients make randomized trials unrealistic, especially when the alternative treatments are radically different -as in the case of surgery and medical management. Problems also arise if the investigators themselves simply refuse to accept randomization. For instance, a randomized, controlled trial comparing carotid-artery stenting and carotid endarterectomy has been planned and funded by the National Institutes of Health. 10 Its success depends on participating surgeons' and interventionists' allowing randomization of their eligible, consenting patients. If, instead, established patient-referral patterns continue, with each specialty treating whoever comes its way, selection bias may confound real differences in treatment. In general, there is insufficient evaluation by randomized, controlled trials of medical devices and surgical procedures.
When recruitment of patients for a randomized, controlled trial is exceptionally difficult, threatening to make the sample of patients unrepresentative, neither reliance on randomized, controlled trials nor reliance on observational studies is wholly satisfactory. 11 Investigators should avoid premature judgments about therapeutic claims and overcome their prejudices against experimentation so that the necessary randomized, controlled trials can be performed. Making the trials as much like routine practice as possible may help to make randomized, controlled trials more feasible and their results more widely generalizable.
Observational data bases can be useful adjuncts to randomized, controlled trials, to see whether efficacy under controlled conditions in specialist centers translates into effective treatment in routine practice. A recent investigation of antiretroviral therapy for human immunodeficiency virus infection 12 concluded that bias in observational research does exist but is not inevitable, especially if the factors used for adjustment strongly predict the outcome. Furthermore, observational studies are useful guides to the design of new controlled trials.
Surely, society expects us to evaluate new healthcare interventions by the most scientifically sound and rigorous methods available. Although observational studies often are cheaper, quicker, and less difficult to carry out, we should not lose sight of one simple fact: ignorance calls for careful experimentation. This means high-quality randomized, controlled trials, not observations that reflect personal choices and beliefs. The key is to persuade physicians, patients, researchers, and study sponsors to collaborate on major trials, with the necessary patients, treatments, outcome measures, sample sizes, and follow-up to resolve therapeutic uncertainty properly. In some areas this is difficult, but perhaps we have not tried hard enough to convert the skeptics. Evaluation in health care has become much more stringent than it once was. Rather than turn the clock back, we should build on these efforts, so as to serve future patients with the most reliable information possible. 
